The Hepatitis Foundation of NZ

New data show that a significant number of patients with chronic hepatitis B virus infection who received PEGASYS® (peginterferon alfa-2a) treatment achieved clearance of a blood antigen known as hepatitis B s-antigen (HBsAg). Clearance of this marker is associated with favourable clinical outcomes, and is as close to a cure as possible in this disease. HBsAg clearance shows that an individual's own immune system is able to control the infection. None of the nucleoside/nucleotide analogue treatments for hepatitis B virus (HBV) have shown such a result.
Read full article.

Hepatitis B experts at loggerheads

POOR prescribing habits by liver specialists are creating resistance to the first drugs able to combat the serious side effects of hepatitis B. And unless doctors modify their ways, the same thing will happen to drugs introduced to replace them.
Read full article.